Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAlyssa M. KanegaiAFAyesha FraserHSHrishikesh K. Srinagesh

Discussion

Loading...

Member takes

Overview

Phase 1 trials demonstrate improved relapse prevention and similar toxicity in allogeneic CAR-T with regulatory T cells for high-risk B-ALL.

Key Points

  • CAR persistence was longer with allogeneic CAR19/22 compared to autologous therapy, supporting its efficacy.
  • At 2.5 years follow-up, the estimated overall survival for the autologous cohort was 77%, while the allogeneic cohort reached 100%.
  • Evaluation through phase 1 trials indicated comparable toxicity profiles in both arms, with mild adverse events reported.
  • The study highlights the potential of regulatory T cells to maintain long-term CAR persistence in patients with B-ALL.

Cite This Study

Kanegai et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e194https://doi.org/10.1182/blood-2025-514
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy2025
  3. 3Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025
  4. 4Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results2025
  5. 5Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors2025